Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Myeloid-Derived Suppressor Cells in B Cell Malignancies Publisher Pubmed



Yazdani Y1 ; Mohammadniaafrouzi M2 ; Yousefi M3, 4 ; Anvari E5 ; Ghalamfarsa G6 ; Hasannia H7 ; Sadreddini S3 ; Jadidiniaragh F7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Infectious Diseases Research Center and Laboratory Science Research Center, Golestan University of Medical Sciences, Gorgan, Iran
  2. 2. Department of Immunology and Microbiology, School of Medicine, Babol University of Medical Sciences, Babol, Iran
  3. 3. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  4. 4. Department of Immunology, Tabriz University of Medical Sciences, Tabriz, Iran
  5. 5. Department of Physiology, Ilam University of Medical Sciences, Ilam, Iran
  6. 6. Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
  7. 7. Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: Tumor Biology Published:2015


Abstract

Tumor cells use several mechanisms such as soluble immune modulators or suppressive immune cells to evade from anti-tumor responses. Immunomodulatory cytokines, such as transforming growth factor-β, interleukin (IL)-10, and IL-35, soluble factors, such as adenosine, immunosuppressive cells, such as regulatory T cells, NKT cells and myeloid-derived suppressor cells (MDSCs), are the main orchestra leaders involved in immune suppression in cancer by which tumor cells can freely expand without immune cell-mediated interference. Among them, MDSCs have attracted much attention as they represent a heterogenous population derived from myeloid progenitors that are expanded in tumor condition and can also shift toward other myeloid cells, such as macrophages and dendritic cells, after tumor clearing. MDSCs exert their immunosuppressive effects through various immune and non-immune mechanisms which make them as potent tumor-promoting cells. Although, there are several studies regarding the immunobiology of MDSCs in different solid tumors, little is known about the precise characteristics of these cells in hematological malignancies, particularly B cell malignancies. In this review, we tried to clarify the precise role of MDSCs in B cell-derived malignancies. © 2015, International Society of Oncology and BioMarkers (ISOBM).
Other Related Docs
18. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
20. Myeloid-Derived Suppressor Cells in Gastrointestinal Cancers: A Systematic Review, Journal of Gastroenterology and Hepatology (Australia) (2016)
23. Cancer Immunology, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
26. Cancer Immunology, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
27. Toll-Like Receptor Pathway and Its Targeting in Treatment of Cancers, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
29. Roles of Myeloid-Derived Suppressor Cells in Cancer Metastasis: Immunosuppression and Beyond, Archivum Immunologiae et Therapiae Experimentalis (2019)
34. Toll-Like Receptor Pathway and Its Targeting in Treatment of Cancers, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers (2015)